These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 30247203)
1. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive. Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. Haugh A; Daud AI Am J Clin Dermatol; 2024 May; 25(3):407-419. PubMed ID: 38329690 [TBL] [Abstract][Full Text] [Related]
3. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma? Hadfield MJ; Sullivan RJ Cancer J; 2024 Mar-Apr 01; 30(2):84-91. PubMed ID: 38527261 [TBL] [Abstract][Full Text] [Related]
4. Treatment management for Haist M; Stege H; Rogall F; Tan Y; von Wasielewski I; Klespe KC; Meier F; Mohr P; Kähler KC; Weichenthal M; Hauschild A; Schadendorf D; Ugurel S; Lodde G; Zimmer L; Gutzmer R; Debus D; Schilling B; Kreuter A; Ulrich J; Meiss F; Herbst R; Forschner A; Leiter U; Pfoehler C; Kaatz M; Ziller F; Hassel JC; Tronnier M; Sachse M; Dippel E; Terheyden P; Berking C; Heppt MV; Kiecker F; Haferkamp S; Gebhardt C; Simon JC; Grabbe S; Loquai C J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730278 [TBL] [Abstract][Full Text] [Related]
5. Real-World Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy. Marcon IG; Valsecchi D; Durso L; Premoli E; Sangiorgi D; Perrone V; Catena L; Degli Esposti L Adv Ther; 2023 Sep; 40(9):3875-3895. PubMed ID: 37368101 [TBL] [Abstract][Full Text] [Related]
6. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Dobry AS; Zogg CK; Hodi FS; Smith TR; Ott PA; Iorgulescu JB Cancer Immunol Immunother; 2018 Dec; 67(12):1833-1844. PubMed ID: 30191256 [TBL] [Abstract][Full Text] [Related]
7. BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series. Strelnikov J; Zhou A; Butt O; Ansstas M; Ansstas G J Natl Compr Canc Netw; 2023 Aug; 21(10):991-999. PubMed ID: 37647938 [TBL] [Abstract][Full Text] [Related]
8. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma. Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S BMC Cancer; 2017 Aug; 17(1):584. PubMed ID: 28851300 [TBL] [Abstract][Full Text] [Related]
10. The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting. Kopecký J; Pásek M; Lakomý R; Melichar B; Mrazová I; Kubeček O; Arenbergerová M; Lemstrová R; Švancarová A; Tretera V; Hlodáková A; Žváčková K Cancer Med; 2024 Mar; 13(5):e6982. PubMed ID: 38491825 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study. Rigo R; Ding PQ; Batuyong E; Cheung WY; Walker J; Monzon JG; Cheng T Oncologist; 2024 Jan; 29(1):57-66. PubMed ID: 37648247 [TBL] [Abstract][Full Text] [Related]
12. Use of ctDNA in identifying an actionable BRAF mutation in stage 4 metastatic melanoma. Bennett C; Morgan S; Aboud K; Frazer RD BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37348922 [TBL] [Abstract][Full Text] [Related]